ClinicalTrials.gg
RecruitingNCT06611618PowerAGINGUpdated Nov 9, 2026

Analysis of the Loss of Muscle Force, Power and Motor Control to Predict the Risk of Falls in Patients With Knee OA

An interventional study of Muscle power assessment and Muscle force assessment in Knee Osteoarthritis (Knee OA) and Falls Prevention, sponsored by Istituto Ortopedico Rizzoli. Recruiting at 1 site in Italy. Open to participants aged 65 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Istituto Ortopedico Rizzoli · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.
Updated Nov 9, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
65 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli — 13 open to participants now, 13 under way, none of them phase 3. Osteoarthritis, Knee · Istituto Ortopedico Rizzoli.

Planned enrollment
13th of 25
50 · median 50
Started
2025
with 2 others
No phase
21 of 31
11 open now
Primary completion
2028-12
later than 11 of 12 live
Registered
30th of 31
by date

Among the 31 studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli, this one is the 13th largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2025, is one of 21 with no phase, reaches primary completion later than 11 of the 12 other live ones, and was the 30th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

13 of the 31 studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 65 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Osteoarthritis, Knee by Istituto Ortopedico Rizzoli, or all of them as a file.
02

Study summary

The twofold goal of this study is to understand the link between muscle power, muscle strength, and muscle control degradation with the risk of falling, and to develop a framework for the comprehensive and quantitative assessment of muscle power (and strength) in an elderly population of patients with knee osteoarthritis, who are at higher risk of falling. The main question it aims to answer is:

● Are muscle power and motor control degradation better predictors of falls than muscle strength in the aging population?

Participants will undergo:

  • Muscle force assessment on a dynamometer
  • Muscle power assessment on a dynamometer and on isntrumented stairs
  • Home-based mobility monitoring
  • Full lower limb MRI acquisition
  • Gait assessment
Read the detailed description

Falls are a critical yet common event among the elderly, with huge societal and economic impact (reduced quality of life and high costs for the healthcare system). Experimental measures to quantify the residual muscle strength and power may provide useful information to predict the risk of falls in the elderly. Isometric and isokinetic muscle contractions, performed on a dynamometer or during functional tasks can be collected, together with electromyography (to assess muscle activity) and imaging data (to quantify and characterize muscular tissue).

Such data can be collected at different time points to monitor subjects over time, and to inform virtual representation of the human musculoskeletal system (digital twins) to identify possible motor control deficits. Moreover, this same information can be used to better characterize/assess elder individuals at risk of falling (e.g., subjects with knee osteoarthritis), to prevent future falls.

All subjects enrolled in the PowerAGING study will be followed up for 24 months (5 visits in total: M0, M6, M12, M18 and M24 follow-up). At each visit, a series of experimental tests to quantify muscle power and muscle force, as well as a home-based mobility assessment (via single inertial sensor worn for 5 consecutive days), will be performed. In addition, only at start and end, the subjects will undergo a full lower limb MRI and a gait assessment.

03

Conditions studied

  • Knee Osteoarthritis (Knee OA)
  • Falls Prevention

Keywords

  • Falls prevention
  • Knee osteoarthritis
  • Muscle power
  • Muscle force
  • Motor control degradation
  • digital twins
  • IMU
  • mobility monitoring
  • MRI
04

Who can participate

Ages eligible
65 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 65 and 80 years
  • Kellgren score II e III
  • No history of falls in the last 12 months

Exclusion criteria

Exclusion Criteria:

  • Any musculoskeletal, neurological, rheumatic or tumoral diseases
  • Dementia
  • Diabetes
  • Inguinal or abdominal hernia
  • Severe Hypertension (Level 3)
  • Severe Cardio-pulmonary insufficiency
  • Diagnosis of Osteonecrosis in the lower limb joints
  • Pathologies or physical conditions incompatible with the use of magnetic resonance imaging and electrostimulation (i.e., active and passive implanted biomedical devices, epilepsy, severe venous insufficiency in the lower limbs)
  • Previous interventions or traumas to the joints of the lower limb
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Knee Osteoarthritis

    Elderly patients with knee osteoarthritis, without a history of falls (in the 12 months prior to enrollment). All subjects will be followed up for 24 months, every 6 months. Muscle force and power assessments, plus a home-based mobility monitoring, will be performed at all visits. Full lower limb MRI and a gait assessment will be performed at first and last visit.

    Other: Muscle power assessment · Other: Muscle force assessment · Other: Home-based mobility monitoring · Diagnostic Test: Magnetic Resonance Imaging · Other: Gait assessment

Interventions

  • OtherMuscle power assessment

    Isokinetic dynamometry test Stair ascent/descent on instrumented stairs

  • OtherMuscle force assessment

    Isometric dynamometry (Maximal Voluntary Isometric Contraction)

  • OtherHome-based mobility monitoring

    Mobility monitoring with wearable sensors

  • Diagnostic testMagnetic Resonance Imaging

    Full lower limb MRI

  • OtherGait assessment

    Motion capture, surface EMG and gorund reaction force data

06

What researchers measure

Primary outcomes

  1. Maximal muscle force

    Maximal Isometric muscle force from dynamometry test

    Time frame: At baseline (Day 0) and all follow-up visits (Month 6, Month 12, Month 18, Month 24)

  2. Muscle power

    Assessed on the dynamometer and during dynamic tasks

    Time frame: At baseline (Day 0) and all follow-up visits (Month 6, Month 12, Month 18, Month 24)

  3. Muscle activations

    From surface EMG data collected on the dynamometer and during dynamic tasks (gait assessment and stair ascent/descent)

    Time frame: At baseline (Day 0) and all follow-up visits (Month 6, Month 12, Month 18, Month 24)

  4. Digital Mobility Outcomes

    Qualitative and quantiative measures of real-world mobility (e.g., gait speed, stride length)

    Time frame: At baseline (Day 0) and all follow-up visits (Month 6, Month 12, Month 18, Month 24)

Secondary outcomes

  1. Musculoskeletal model predictions

    Estimates of muscle force and knee joint contact forces

    Time frame: At baseline (Day 0) and all follow-up visits (Month 6, Month 12, Month 18, Month 24)

  2. Muscle volumes

    Estimation of muscle volumes (cm3)

    Time frame: From first follow-up visit (Month 6) to last follow-up visit (Month 24)

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2028, 47 months after the start.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 47 months is above that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Jun 2026 → Dec 2028 and completion Dec 2026 → Jun 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2024
First posted
Sep 25, 2024
StartActual
Jan 30, 2025
Primary completionEst.
Dec 31, 2028was Jun 2026
CompletionEst.
Jun 30, 2029was Dec 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 30, 2026→Dec 31, 2028
Nov 9, 2026
Study completion
Dec 12, 2026→Jun 30, 2029
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Primary completion Jun 30, 2026→Dec 31, 2028
    Study completion Dec 12, 2026→Jun 30, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06611618
Responsible party
Sponsor
First posted
Sep 25, 2024
Start date
Jan 30, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Nov 9, 2026

Study contacts

Lisa Berti, Professor
Contact
lisa.berti@ior.it
+390516366529
Massimiliano Baleani, Engineer
Contact
massimiliano.baleani@ior.it
+390516366865
Lisa Berti, Professor
principal investigator · IRCCS Istituto Ortopedico Rizzoli

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion